- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF, VDV, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C, Chronic
- Interventions
- Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 85
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Chronic Hepatitis C
- Interventions
- GS-5885, GS-9451, RBV, PEG
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 20 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885, Tegobuvir, GS-9451, ribavirin tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Anaheim, California + 34 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment
- Drug · Other
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Not listed
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 158
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 89 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
- Conditions
- Chronic Genotype 1a or 1b HCV Infection
- Interventions
- GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet, placebo matching tegobuvir capsule
- Drug · Device
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 36
- States / cities
- Beverly Hills, California • Coronado, California • La Jolla, California + 28 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Sofosbuvir, Ledipasvir, GS-9669, GS-9451
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Hepatitis C, Chronic
- Interventions
- Not listed
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 162
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more